A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors
The eradication of solid tumors by chimeric antigen receptor (CAR) T cells requires dynamic therapies capable of outlasting an immune suppressive tumor microenvironment (TME). However, biological barriers—including rapid exhaustion, poor expansion, and loss of stem-like memory—quickly neutralize these therapies1. Becau...